{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:32:59Z","timestamp":1757781179647,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["20ZR1408900"],"award-info":[{"award-number":["20ZR1408900"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072877"],"award-info":[{"award-number":["82072877"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lymphovascular space invasion (LVSI) is the first step of hematogenous metastasis. Exploration of the differential miRNA expression profiles between LVSI-positive and LVSI-negative ovarian cancer tissues may help to identify key miRNAs involved in the hematogenous metastasis of ovarian cancer. This study is aimed to identify microRNAs (miRNAs) that are differentially expressed between LVSI-positive and LVSI-negative ovarian cancer tissues, followed by exploring their association with bevacizumab response in ovarian cancer patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Cancer Genome Altas (TGGA) dataset was used to identify the differentially expressed miRNAs between LVSI-positive and LVSI-negative ovarian cancer tissues. The prognostic value of the differentially expressed miRNAs was determined using GSE140082 dataset.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We showed that miR-25 and miR-142 were differentially expressed between LVSI-positive and LVSI-negative ovarian cancer tumors. Kaplan-Meier analysis indicated that high miR-25 expression was associated with increased progression free survival (PFS) and extended overall survival (OS). Moreover, patients with low miR-25 expression benefited significantly from bevacizumab treatment in terms of PFS. A similar trend was observed in terms of OS though without reaching statistical significance. In contrast, no significant survival benefits from bevacizumab were observed in patients with high miR-25 expression in terms of PFS and OS. There was no significant correlation between miR-142 expression and PFS. In contrast, high miR-142 expression was associated with reduced OS. Moreover, patients with high miR-142 expression benefited significantly from bevacizumab treatment in terms of PFS and OS. However, bevacizumab treatment conferred no significant improvements in both PFS and OS in patients with low miR-142 expression. The nomogram for PFS indicated that miR-25 expression had a larger contribution to PFS than debulking status and bevacizumab treatment. And the nomogram for OS illustrated both miR-25 expression and miR-142 expression as sharing a larger contribution to OS than bevacizumab treatment and debulking status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, miR-25 expression correlates with a better PFS and OS in ovarian cancer. Patients with low miR-25 expression and high miR-142 expression could benefit from bevacizumab treatment significantly.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-021-00915-9","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T04:41:14Z","timestamp":1637556074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression"],"prefix":"10.1186","volume":"14","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiran","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1684-4465","authenticated-orcid":false,"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"issue":"27","key":"915_CR1","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1200\/JCO.19.00022","volume":"37","author":"A du Bois","year":"2019","unstructured":"du Bois A, Baert T, Vergote I. Role of neoadjuvant chemotherapy in advanced epithelial ovarian Cancer. J Clin Oncol. 2019;37(27):2398\u2013405.","journal-title":"J Clin Oncol"},{"issue":"17","key":"915_CR2","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers13174318","volume":"13","author":"BP Rickard","year":"2021","unstructured":"Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, et al. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers (Basel). 2021;13(17):4318.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"915_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ccell.2016.06.020","volume":"30","author":"F Miranda","year":"2016","unstructured":"Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, et al. Salt-inducible kinase 2 couples ovarian cancer cell metabolism with survival at the adipocyte-rich metastatic niche. Cancer Cell. 2016;30(2):273\u201389.","journal-title":"Cancer Cell"},{"issue":"1","key":"915_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","volume":"26","author":"S Pradeep","year":"2014","unstructured":"Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014;26(1):77\u201391.","journal-title":"Cancer Cell"},{"issue":"7","key":"915_CR5","doi-asserted-by":"publisher","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","volume":"309","author":"TL Yeung","year":"2015","unstructured":"Yeung TL, Leung CS, Yip KP, Au YC, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444\u201356.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"11","key":"915_CR6","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.3390\/cancers13112613","volume":"13","author":"E Obermayr","year":"2021","unstructured":"Obermayr E, Reiner A, Brandt B, Braicu EI, Reinthaller A, Loverix L, et al. The long-term prognostic significance of circulating tumor cells in ovarian cancer-a study of the OVCAD Consortium. Cancers (Basel). 2021;13(11):2613.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"915_CR7","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W. Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"915_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13048-019-0524-2","volume":"12","author":"J Li","year":"2019","unstructured":"Li J, Yue H, Yu H, Lu X, Xue X. Development and validation of SIRT3-related nomogram predictive of overall survival in patients with serous ovarian cancer. J Ovarian Res. 2019;12(1):47.","journal-title":"J Ovarian Res"},{"issue":"1","key":"915_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1186\/s12885-019-6470-y","volume":"19","author":"H Yue","year":"2019","unstructured":"Yue H, Wang J, Chen R, Hou X, Li J, Lu X. Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer. BMC Cancer. 2019;19(1):1266.","journal-title":"BMC Cancer"},{"issue":"11","key":"915_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s12094-014-1178-6","volume":"16","author":"X Wang","year":"2014","unstructured":"Wang X, Meng X, Li H, Liu W, Shen S, Gao Z. MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Transl Oncol. 2014;16(11):954\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"915_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/bjc.2015.340","volume":"113","author":"X Meng","year":"2015","unstructured":"Meng X, Joosse SA, Muller V, Trillsch F, Milde-Langosch K, Mahner S, et al. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. Br J Cancer. 2015;113(9):1358\u201366.","journal-title":"Br J Cancer"},{"issue":"2 Pt B","key":"915_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.canlet.2014.10.010","volume":"356","author":"R Langhe","year":"2015","unstructured":"Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, et al. A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Lett. 2015;356(2 Pt B):628\u201336.","journal-title":"Cancer Lett"},{"key":"915_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.canlet.2020.11.014","volume":"501","author":"AT Khani","year":"2021","unstructured":"Khani AT, Sharifzad F, Mardpour S, Hassan ZM, Ebrahimi M. Tumor extracellular vesicles loaded with exogenous Let-7i and miR-142 can modulate both immune response and tumor microenvironment to initiate a powerful anti-tumor response. Cancer Lett. 2021;501:200\u20139.","journal-title":"Cancer Lett"},{"key":"915_CR14","doi-asserted-by":"publisher","first-page":"e01977","DOI":"10.7554\/eLife.01977","volume":"3","author":"T Isobe","year":"2014","unstructured":"Isobe T, Hisamori S, Hogan DJ, Zabala M, Hendrickson DG, Dalerba P, et al. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. Elife. 2014;3:e01977.","journal-title":"Elife"},{"issue":"30","key":"915_CR15","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1038\/s41388-021-01891-6","volume":"40","author":"J Zhang","year":"2021","unstructured":"Zhang J, Guan W, Xu X, Wang F, Li X, Xu G. A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4\/ZEB1\/miR-142-5p in human ovarian cancer. Oncogene. 2021;40(30):4906\u201318.","journal-title":"Oncogene"},{"key":"915_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bcp.2019.01.009","volume":"161","author":"X Li","year":"2019","unstructured":"Li X, Chen W, Jin Y, Xue R, Su J, Mu Z, et al. Jiang S: miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem Pharmacol. 2019;161:98\u2013112.","journal-title":"Biochem Pharmacol"},{"issue":"26","key":"915_CR17","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"},{"issue":"26","key":"915_CR18","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"1","key":"915_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-018-0844-7","volume":"17","author":"H Liang","year":"2018","unstructured":"Liang H, Zhao X, Wang C, Sun J, Chen Y, Wang G, et al. Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer. Mol Cancer. 2018;17(1):96.","journal-title":"Mol Cancer"},{"issue":"1","key":"915_CR20","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1038\/s41467-020-18633-z","volume":"11","author":"NW Hultgren","year":"2020","unstructured":"Hultgren NW, Fang JS, Ziegler ME, Ramirez RN, Phan D, Hatch M, et al. Slug regulates the Dll4-Notch-VEGFR2 axis to control endothelial cell activation and angiogenesis. Nat Commun. 2020;11(1):5400.","journal-title":"Nat Commun"},{"issue":"9","key":"915_CR21","doi-asserted-by":"publisher","first-page":"12359","DOI":"10.18632\/aging.203035","volume":"13","author":"Q Roblain","year":"2021","unstructured":"Roblain Q, Louis T, Yip C, Baudin L, Struman I, Caolo V, et al. Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization. Aging (Albany NY). 2021;13(9):12359\u201377.","journal-title":"Aging (Albany NY)"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00915-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-021-00915-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00915-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T04:41:52Z","timestamp":1637556112000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00915-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00915-9","relation":{},"ISSN":["1757-2215"],"issn-type":[{"type":"electronic","value":"1757-2215"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data for the present study were obtained from TCGA and GEO databases, which have received ethics approval and consent to participate. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Data for the present study were obtained from TCGA and GEO databases, which have received consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}